| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Labcorp Holdings Inc.$275.77
+3.77 (+1.39%)
D 36Pipeline Score Diagnostics · Commercial
Market Cap
21.50 B
EPS
10.54
P/E Ratio
24.95 $
Value Trade
175.40 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.54 B
Operating CF
191.50 M
Total Assets
19.09 B
Total Liabilities
10.34 B
Equity
8.73 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
1.18 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
150.25 K
52 Week Range
209.38 - 293.72
% held by Insiders
0.4 %
% held by Institutions
99.73 %
Enterprise Value
27.51 B
Total Shares
82.40 M
Short %
3.47 %
Float Shares
82.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Labcorp Holdings Inc.
232Total events
1Upcoming
62Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲FDA ApprovalColoSenseApprovedFDA Decision
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D36
Pipeline Score $530M
Pipeline ValueValuation Signal
3
Drugs Scored0.0x
rNPV / MCap Top 49%
Mid Cap (rank 466 of 912)
Percentile RankLabcorp Holdings Inc. faces pipeline headwinds (36/100), with $624M risk-adjusted pipeline value, led by VIT-2763 once a day in Beta-Thalassemia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIT-2763 once a day Small molecule | Beta-Thalassemia | Phase 2 | NCT04364269 | 60% | $431M | COMPLETED | 35 | - | - | Nov 3, 2021 | - | Dec 14, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LH
Jul 9, 2026Labcorp Declares Quarterly Dividend
Labcorp Holdings Inc. has declared a quarterly cash dividend of $0.72 per share. This dividend will be payable on September 11, 2026, to stockholders on record by August 28, 2026. The announcement reflects Labcorp's ongoing commitment to returning value to its shareholders while maintaining its leadership in laboratory services.
Read more →-LH
Jun 30, 2026Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
Labcorp Holdings Inc. will announce its financial results for Q2 2026 on July 30, 2026. The announcement will occur before market opening, followed by a webcast at 9:00 a.m. ET. Financial details will be available on their Investor Relations website, with a replay accessible for one year post-event.
Read more →-LH
Jun 22, 2026Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
Labcorp has announced the nationwide availability of ColoSense®, the first FDA-approved RNA-based at-home colorectal cancer screening test. This innovative test aims to improve screening rates by offering a simplified collection process that minimizes discomfort and handling. ColoSense is covered for eligible Medicare beneficiaries and aligns with leading cancer screening guidelines, demonstrating high sensitivity for early-stage colorectal cancer detection.
Read more →-LH
Jun 8, 2026GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
GENFIT has announced the launch of its NASHnext® test through Labcorp OnDemand, aimed at identifying patients with at-risk MASH. This non-invasive diagnostic tool, powered by GENFIT's NIS4® technology, allows for broader access to testing without the need for in-person visits. The initiative addresses significant diagnostic gaps in routine care, especially for patients with metabolic risk factors.
Read more →-LH
Jun 8, 2026GENFIT annonce que NASHnext® de Labcorp, basé sur sa technologie diagnostique non invasive NIS4® pour l’identification de la MASH à risque, est lancé via la plateforme « Labcorp OnDemand »
GENFIT has announced the launch of the NASHnext® test via Labcorp OnDemand, utilizing its proprietary NIS4® technology. This non-invasive diagnostic tool aims to identify patients at risk of Metabolic dysfunction-Associated SteatoHepatitis (MASH). The initiative is designed to broaden access and facilitate early detection among a larger patient population, potentially benefiting millions in the U.S.
Read more →-LH
May 29, 2026Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Labcorp has announced a collaboration with the Alliance for Clinical Trials in Oncology to conduct a national trial aimed at enhancing germline genetic testing in colorectal cancer patients and their at-risk family members. The trial will explore proactive outreach by healthcare providers to improve testing rates and assess the impact of multigene panel testing on patient care. The study is sponsored by the National Cancer Institute and aims to generate real-world evidence to improve genetic risk identification.
Read more →-LH
May 28, 2026Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
Labcorp has launched an expanded DPYD Genotyping test to identify cancer patients at risk of severe side effects from fluoropyrimidine chemotherapy. This test detects all DPYD variants recommended by the Association for Molecular Pathology, enabling safer and more personalized treatment. The initiative aims to reduce the risk of severe toxicity and improve patient outcomes in cancer care.
Read more →-LH
May 27, 2026Labcorp to Present at the Jefferies Global Healthcare Conference
Labcorp will present at the 2026 Jefferies Global Healthcare Conference on June 3. The presentation will be accessible via a live webcast and will be archived for later viewing. Labcorp is recognized for its comprehensive laboratory services, supporting a significant portion of new drug approvals.
Read more →-LH
May 27, 2026Document FOR IMMEDIATE RELEASE Media Investors Racquel White Dewey Steadman Media Labcorp.com Investor Labcorp.com Labcorp to Present at the Jefferies Global Healthcare Conference BURLINGTON, N.C., (
Labcorp (NYSE LH) has announced its upcoming presentation at the 2026 Jefferies Global Healthcare Conference, scheduled for June 3. This event underscores Labcorp's role as a leader in laboratory services, providing essential support to healthcare providers and pharmaceutical companies globally. The presentation will be accessible via a live webcast, with an archived recording available for 90 days post-event. With almost 71,000 employees, Labcorp plays a key role in advancing healthcare through diagnostics and drug development.
Read more →-LH
Apr 30, 2026Document FOR IMMEDIATE RELEASE Contact Dewey Steadman - Investors Racquel White - Media Investor labcorp.com Media labcorp.com Labcorp Announces 2026 First Quarter Results Raises Full Year 2026 Guidance Results from Oper
Labcorp Holdings Inc. has announced its first quarter results for 2026, showcasing a revenue increase to $3.54 billion, up 5.8% from the previous year. The company reported a diluted EPS of $3.35, a significant rise of 32.8% year-over-year. Due to this strong performance, Labcorp has raised its full-year guidance for both revenue and Adjusted EPS. The company continues to expand its strategic collaborations and invest in advanced technologies, which are expected to drive further growth.
Read more →-LH
Apr 22, 2026Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
Labcorp has launched the PD-L1 IHC 22C3 pharmDx, the first FDA-approved companion diagnostic for identifying patients with platinum-resistant ovarian cancer eligible for KEYTRUDA. This diagnostic aims to improve treatment options for patients facing recurrence after initial therapy. With approximately 80% of ovarian cancer patients experiencing recurrence, this advancement could significantly impact survival outcomes.
Read more →-LH
Apr 14, 2026Children’s Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Labcorp and the Children's Hospital of Philadelphia have announced a strategic collaboration to enhance pediatric diagnostics across the U.S. This partnership aims to leverage CHOP's clinical expertise and Labcorp's diagnostic infrastructure to develop specialized tests for children. The initiative focuses on improving access to advanced diagnostics in areas such as oncology and metabolic diseases.
Read more →-LH
Apr 14, 2026Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
Labcorp has launched an AI-powered real-world data platform to enhance Alzheimer's research. Developed in collaboration with AWS and Datavant, this platform streamlines data analysis, allowing researchers to generate insights rapidly. With over 7.2 million Americans affected by Alzheimer's, this innovation aims to accelerate drug development and improve patient outcomes.
Read more →-LH
Apr 13, 2026Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Labcorp and Children's Hospital of Philadelphia have announced a strategic collaboration to enhance pediatric diagnostics across the U.S. This partnership aims to leverage CHOP's clinical expertise and Labcorp's diagnostic capabilities to develop and distribute specialized tests for children. The initiative focuses on improving access to advanced diagnostics in areas like oncology and metabolic diseases.
Read more →-LH
Apr 9, 2026Document FOR IMMEDIATE RELEASE Media Investors Racquel White Dewey Steadman Media Labcorp.com Investor Labcorp.com Labcorp Declares Quarterly Dividend BURLINGTON, N.C.
Labcorp Holdings Inc. has declared a quarterly cash dividend of $0.72 per share, payable on June 11, 2026, to shareholders of record by May 29, 2026. The announcement highlights Labcorp's robust financial position and commitment to returning value to its investors. With nearly 71,000 employees and operations in approximately 100 countries, Labcorp plays a crucial role in supporting drug development and diagnostics.
Read more →-LH
Apr 1, 2026Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp Holdings Inc. is set to announce its first quarter financial results for 2026 on April 30, 2026. The announcement will occur before market opening, followed by a webcast at 9:00 a.m. ET. The earnings press release will be available on their Investor Relations website, along with a replay of the webcast.
Read more →-LH
Mar 31, 2026Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Dewey Steadman Media Labcorp.com Investor Labcorp.com Labcorp to Announce First Quarter Financial Results on
Labcorp Holdings Inc. is set to release its financial results for the first quarter of 2026 on April 30, 2026. The announcement will precede the market opening, followed by a webcast discussion at 9:00 a.m. ET. Labcorp emphasizes its role in supporting over 85% of new drugs approved by the FDA in 2025 and highlights its extensive laboratory service capabilities. A replay of the webcast will be accessible for one year after the live event.
Read more →-LH
Feb 23, 2026Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
Labcorp has announced an expanded collaboration with PathAI to deploy the FDA-cleared AISight® Dx digital pathology platform across its network of anatomic pathology labs. This initiative aims to enhance efficiency and patient care through AI-enabled insights and fully digital workflows. The partnership builds on a previous investment made in 2019, further advancing AI-driven clinical trial support.
Read more →-LH
Feb 17, 2026Labcorp Announces 2025 Fourth Quarter and Full Year Results
Labcorp Holdings Inc. reported strong financial results for the fourth quarter and full year of 2025, highlighting over 7% revenue growth and double-digit adjusted EPS growth. The company is optimistic about its performance in 2026, driven by advancements in its Diagnostics and Central Laboratory businesses. Additionally, Labcorp announced a cash dividend and significant stock repurchases.
Read more →-LH
Feb 17, 2026Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O'Donnell Media labcorp.com Investor labcorp.com Labcorp Announces 2025 Fourth Quarter and Full Year Results Company Provides 2026 Guidance Financial re
Labcorp announced its financial results for the fourth quarter and full year of 2025, reporting revenue of $3.52 billion for Q4 and $13.95 billion for the full year. The company also provided guidance for 2026, expecting revenue growth of 5.4% and adjusted EPS growth of 8.9%. Labcorp's strong performance was driven by its Diagnostics and Central Laboratory businesses, alongside significant progress in expanding partnerships and launching innovative tests. However, the firm saw a decrease in free cash flow and operating cash flow compared to the previous quarter and year, respectively.
Read more →-LH
Feb 11, 2026Labcorp Launches First FDA-Cleared Blood Test for Alzheimer’s Disease Assessment in Primary Care
Labcorp has launched the Elecsys pTau-181 test, the first FDA-cleared blood test for assessing Alzheimer's disease in primary care. This test enables primary care clinicians to rule out Alzheimer's by identifying patients unlikely to have amyloid pathology. It aims to facilitate earlier diagnosis and guide further testing for cognitive decline.
Read more →-LH
Feb 9, 2026Document FOR IMMEDIATE RELEASE Neil Hirsch - Media Christin O'Donnell - Investors Media Labcorp.com Investor Labcorp.com Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors BURLINGTON, N.C., (
Labcorp Holdings Inc. has appointed John H. Sampson, M.D., Ph.D., to its Board of Directors, effective February 9, 2026. Dr. Sampson is a respected leader in academic medicine and brings significant expertise in oncology, neuroscience, and personalized medicine, which align with Labcorp's strategic goals. His prior leadership roles at Duke University Health System and his extensive research background will contribute to Labcorp's mission of advancing diagnostics and drug development. He has been assigned to the Quality and Compliance Committee of the Board.
Read more →-LH
Jan 15, 2026Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp to Announce Fourth Quarter Financial Results on
Labcorp Holdings Inc. plans to announce its fourth quarter financial results for 2025 on February 17, 2026. The release will occur before market opening, followed by a conference call and webcast at 9 a.m. ET. Participants are encouraged to register in advance to obtain dial-in details. The recorded webcast will be available for a year after the event.
Read more →-LH
Jan 14, 2026Document FOR IMMEDIATE RELEASE Media Investors Media Labcorp.com Investor Labcorp.com Labcorp Declares Quarterly Dividend BURLINGTON, N.C.
Labcorp Holdings Inc. has announced a cash dividend of $0.72 per share, payable on March 12, 2026, for its stockholders of record by February 27, 2026. This decision reflects the company's strong performance in laboratory services and its role in supporting new drug approvals. Labcorp is known for its innovative testing and development capabilities, employing nearly 70,000 individuals and providing services in around 100 countries. The announcement underscores the company's commitment to enhancing healthcare through diagnostics and research.
Read more →-LH
Jan 13, 2026Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
Labcorp has expanded its molecular residual disease (MRD) testing portfolio to include new tests for breast, lung, and colon cancer. The Labcorp Plasma Detect ID and Genome tests aim to detect cancer recurrence earlier than traditional methods by identifying circulating tumor DNA in the bloodstream. This expansion supports personalized care and improves patient access to non-invasive testing options.
Read more →-LH
Jan 9, 2026NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
NAMSA has successfully acquired the Early Development medical device testing business from Labcorp, enhancing its service offerings for MedTech manufacturers. This acquisition allows NAMSA to provide a broader range of testing and regulatory consulting services, while Labcorp can concentrate on its primary areas of drug development. The transition aims to maintain high service levels for existing Labcorp clients.
Read more →-LH
Jan 9, 2026Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
Visby Medical has partnered with Quest Diagnostics and Labcorp to enhance access to its at-home Women's Sexual Health Test, the first FDA-authorized PCR test for STIs. This test provides lab-quality results in just 30 minutes, allowing for immediate treatment options. The collaboration aims to address the urgent need for accessible STI testing, particularly for women, who often face barriers to care.
Read more →-LH
Dec 30, 2025Document FOR IMMEDIATE RELEASE Media Investor Relations Media Labcorp.com Investor Labcorp.com Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference BURLINGTON, N.C., (
Labcorp (NYSE: LH) announced that it will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 13, 2026. The event will be available live via the company's Investor Relations website and will later be archived for replay. Labcorp is recognized for its comprehensive laboratory services, contributing to over 75% of new drug approvals by the FDA in 2024, reflecting its significant role in the healthcare industry.
Read more →-LH
Dec 10, 2025Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp Announces Retirement of Dr. D. Gary Gilliland from its Board of Directors BURLINGTON,
Labcorp Holdings Inc. announced the retirement of Dr. D. Gary Gilliland from its board of directors, effective December 31, 2025. Dr. Gilliland has been on the board since 2014, providing essential leadership and insight, particularly in oncology and gene therapy. Both Labcorp's CEO and lead independent director praised his substantial contributions over his tenure. The company remains focused on innovation and improving health outcomes as it continues to serve clients worldwide.
Read more →-LH
Nov 24, 2025Document FOR IMMEDIATE RELEASE Contact Neil Hirsch - Media Media labcorp.com Christin O'Donnell - Investors Investor labcorp.com Labcorp Appoints Victor Bulto to Board of Directors Bulto, President, U.S. of Novartis, bri
Labcorp has appointed Victor Bulto, the President of Novartis U.S., to its Board of Directors effective December 1, 2025. With 25 years of healthcare experience, Bulto is expected to contribute to Labcorp's long-term strategic goals, particularly in innovation and patient care. His leadership experience in a major pharmaceutical company is anticipated to bolster Labcorp's efforts to advance solutions in precision medicine. Labcorp CEO Adam Schechter emphasized the importance of Bulto's experience in enhancing the company's growth through innovation.
Read more →-LH
Oct 28, 2025▼ -5.8%on this news
Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O'Donnell Media labcorp.com Investor labcorp.com Labcorp Announces 2025 Third Quarter Results Updates Full-Year Guidance Financial results from Operatio
Labcorp (NYSE LH) announced its third quarter results for 2025, showing an increase in revenue to $3.56 billion compared to $3.28 billion in the same quarter of 2024. The company also raised its adjusted EPS guidance by $0.05 amidst strong cash flow. Although Labcorp signed several strategic agreements and advanced its specialty testing areas, it lowered its full-year revenue guidance slightly due to currency fluctuations and acquisition timing. Additionally, the company is addressing lower-than-anticipated revenue in its Early Development segment with potential restructuring.
Read more →-LH
Oct 8, 2025Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp Declares Quarterly Dividend BURLINGTON, N.C.
Labcorp Holdings Inc. has announced a cash dividend of $0.72 per share, which will be payable on December 11, 2025. This decision, made by the Board of Directors, reflects the company's financial health and commitment to returning value to shareholders. The company's extensive laboratory services and contributions to new drug approvals further underscore its position as a leader in the healthcare sector. Stockholders of record by November 26, 2025, will be eligible for this dividend.
Read more →-LH
Sep 25, 2025Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp to Announce Third Quarter Financial Results on
Labcorp Holdings Inc. will announce its third quarter financial results on October 28, 2025, before the market opens. The company will conduct a conference call and webcast at 9 a.m. ET to discuss these results. Labcorp emphasizes its leadership in innovative laboratory services, supporting over 75% of new drug approvals in 2024 by the FDA. Interested participants can access the webcast via the Labcorp Investor Relations website.
Read more →-LH
Aug 27, 2025Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference BURLINGTON, N.C., (
Labcorp Holdings Inc. (NYSE: LH) has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The executive management team will engage in a fireside chat, offering insights into the company's innovative laboratory services. A live audio webcast of the event will be available for investors, showcasing Labcorp’s commitment to transparency and stakeholder engagement. This conference is a significant platform for Labcorp to highlight its contributions to healthcare and advancements in diagnostics.
Read more →-LH
Jul 24, 2025▲ +6.9%on this news
Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O'Donnell Media labcorp.com Investor labcorp.com Labcorp Announces 2025 Second Quarter Results Raises Full-Year Guidance Financial results from Operatio
Labcorp (NYSE: LH) announced its financial results for the second quarter of 2025, showcasing significant year-over-year revenue growth and raised full-year guidance. The company's revenue reached $3.53 billion, up from $3.22 billion during the same period in 2024, while adjusted EPS also saw an increase. Labcorp has expanded its partnerships, introduced new tests and services in high-growth areas like oncology, and has plans for future acquisitions to strengthen its offerings. Overall, the company is optimistic about its continued growth and performance in the coming months.
Read more →-LH
Jun 26, 2025Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Christin O'Donnell Media Labcorp.com Investor Labcorp.com Labcorp to Announce Second Quarter Financial Results on
Labcorp Holdings Inc. (NYSE LH) is set to release its second quarter financial results on July 24, 2025. A conference call and webcast will follow the announcement to discuss the results further. The event underscores Labcorp's ongoing role as a leader in laboratory services and its substantial contributions to improving healthcare through diagnostics and drug development.
Read more →-LH
Apr 29, 2025Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin Odonnell Media labcorp.com Investor labcorp.com Labcorp Announces 2025 First Quarter Results Updates Full-Year Guidance Results from Operations for firs
Labcorp (NYSE: LH) announced its first quarter results for 2025, showing a revenue increase to $3.35 billion, up 5.3% from the previous year, though diluted EPS decreased to $2.52. The company reaffirmed its full-year guidance while adjusting the midpoint of adjusted EPS slightly upwards. Notable advancements included the introduction of new diagnostic tests and several acquisitions aimed at broadening its service offerings. Despite these positive developments, challenges such as a decline in diluted EPS and operating income margins were also reported.
Read more →-LH
Mar 31, 2025Document FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Nickolo Russo Media Labcorp.com Investor Labcorp.com Labcorp to Announce First Quarter Financial Results on
Labcorp Holdings Inc. (NYSE LH) is set to announce its first quarter financial results for 2025 on April 29, before the market opens. A conference call and webcast will be held at 9 a.m. ET on that day for discussion of the results, which will also be available for replay afterwards. The company provides comprehensive laboratory services and plays a significant role in supporting drug development and approvals.
Read more →-LH
Feb 6, 2025Document FOR IMMEDIATE RELEASE Media Investors Media Labcorp.com Investor labcorp.com Labcorp Announces 2024 Fourth Quarter and Full Year Results Company Provides 2025 Guidance Results from Continuing Operations versus l
Labcorp Holdings Inc. announced its fourth quarter and full-year 2024 financial results, revealing a significant increase in revenues and earnings. Q4 revenue reached $3.33 billion, up from $3.03 billion the previous year, with adjusted EPS rising to $3.45. The company expects 2025 revenues of $13.88 billion to $14.05 billion and adjusted EPS of $15.60 to $16.40, indicating an optimistic outlook. Additionally, Labcorp initiated ten transactions and launched innovative tests aimed at addressing key medical needs, enhancing its position in the market.
Read more →-LH
Jan 10, 2025Document FOR IMMEDIATE RELEASE Media Investors Media Labcorp.com Investor Labcorp.com Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference BURLINGTON, N.C., (
Labcorp Holdings Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The executive management team will engage in a fireside chat that will be accessible via a live audio webcast on the company's Investor Relations website. With a strong emphasis on innovation and comprehensive laboratory services, Labcorp is a key player in the laboratory sector, impacting healthcare decisions worldwide.
Read more →-LH
Jan 8, 2025Document FOR IMMEDIATE RELEASE Media Investors Media Labcorp.com Investor Labcorp.com
Labcorp Holdings Inc. has announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share. This dividend is set to be payable on March 12, 2025, to stockholders recorded by February 27, 2025. The company positions itself as a leader in laboratory services, contributing to a majority of new drug approvals and performing a vast number of tests globally.
Read more →-LH
Nov 19, 2024Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) Investor Labcorp.com Kimbrel Arculeo (media) Media Labcorp.com Labcorp CFO Glenn Eisenberg Announces Plans to Retire Julia Wang Named Chief Financial
Labcorp's CFO Glenn Eisenberg has announced his retirement effective December 2, 2024, with Julia Wang set to take over the role. Wang brings substantial experience from her previous role as CFO at BeiGene, where she drove significant business transformations. Eisenberg will assist in the transition and strategic initiatives until April 2025. The company emphasizes a commitment to enhancing shareholder value and improving health outcomes under new leadership.
Read more →-LH
Oct 24, 2024Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) Investor Labcorp.com Kimbrel Arculeo (media) Media Labcorp.com Labcorp Announces 2024 Third Quarter Results Updates Full-Year Guidance Results from Co
Labcorp announced its third quarter results for 2024, reporting a revenue increase of 7.4% year-over-year to $3.28 billion. While diluted EPS slightly decreased, adjusted EPS rose to $3.50, reflecting strong performance in core segments. The company also updated its full-year guidance, indicating a robust outlook despite a minor downward adjustment. New acquisitions were highlighted as part of Labcorp's growth strategy to expand testing capabilities and services. Additionally, Labcorp achieved significant advancements in diagnostics technologies and collaborations.
Read more →-LH
Oct 10, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Christin O'Donnell - 336-436-5076 Investor Labcorp.com Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com Labcorp Declares Quarterly Dividend BURLINGTON, N.C.
Labcorp has announced a quarterly cash dividend of $0.72 per share, payable on December 13, 2024, to stockholders on record as of November 26, 2024. The company, based in Burlington, N.C., has established itself as a leader in laboratory services and diagnostics. With over 67,000 employees, Labcorp supports healthcare globally, notably contributing to a significant percentage of new drug approvals by the FDA in 2023.
Read more →-LH
Sep 24, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Investors Kimbrel Arculeo Christin O'Donnell 336-436-8263 336-436-5076 Media Labcorp.com Investor Labcorp.com Labcorp to Announce Third Quarter Financial Results on
Labcorp is set to announce its third quarter financial results on October 24, 2024, prior to market opening. A conference call will be hosted at 9 a.m. ET on the same day to discuss these results. The company emphasizes its leadership in laboratory services and significant contributions to drug approvals in the past year.
Read more →-LH
Sep 16, 2024Labcorp Contacts: Media: Kimbrel Arculeo 336-436-8263 Media@Labcorp.com Investors: Christin O Donnell 336-436-5076 Investor@Labcorp.com LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $
Labcorp Holdings Inc. has announced the pricing of a $650 million offering of senior notes due 2030, along with additional senior notes due in 2032 and 2034. The offering aims to generate funds primarily for debt reduction and general corporate purposes. The anticipated closing date for this offering is September 23, 2024, provided that standard closing conditions are met. Labcorp asserts its commitment to supporting new drug approvals and enhancing its laboratory capabilities.
Read more →-LH
Sep 3, 2024Document FOR IMMEDIATE RELEASE LabCorp Contacts Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com Investors Relations Christin O'Donnell - 336-436-5076 Investor Labcorp.com Labcorp to Speak at the Baird 2024 Global
Labcorp (NYSE LH) has announced that its executive management team will participate in the Baird 2024 Global Healthcare Conference scheduled for September 10, 2024, at 3:10 PM ET. This event highlights Labcorp's position as a leader in laboratory services, supporting healthcare professionals and pharmaceutical companies in decision-making. With over 67,000 employees and a presence in approximately 100 countries, Labcorp has been integral in advancing health through diagnostics and drug development.
Read more →-LH
Aug 1, 2024▲ +8.3%on this news
Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2024 Second Quarter Results Updates Ful
Labcorp (LH) reported its second quarter results for 2024, showcasing significant revenue and earnings growth compared to the previous year. The company achieved a revenue of $3.22 billion, up 6.2%, and a diluted EPS of $2.43, increasing from $1.74. Labcorp also updated its full-year guidance, projecting revenue growth of 6.4% to 7.5%. Additionally, the company announced the approval of its acquisition of assets from Invitae and launched new tests that enhance its portfolio in key therapeutic areas.
Read more →-LH
Jul 25, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Christin O'Donnell - 336-436-5076 Investor Labcorp.com Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com
Labcorp announced a cash dividend of $0.72 per share to be paid on September 13, 2024, to shareholders recorded by August 29, 2024. This announcement underscores the company’s financial health and commitment to returning capital to its shareholders. Labcorp is recognized for its pioneering laboratory services, which significantly contribute to the pharmaceutical industry and healthcare at large. The organization has a notable workforce and has supported a large number of new drug approvals in recent years.
Read more →-LH
Jul 1, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Investors Kimbrel Arculeo Christin O'Donnell 336-436-8263 336-436-5076 Media Labcorp.com Investor Labcorp.com Labcorp to Announce Second Quarter Financial Results on
Labcorp will announce its financial results for the second quarter of 2024 on August 1, before the market opens. A conference call will be held that same day at 9 a.m. ET to discuss the results. The company has a strong reputation in the laboratory services sector, supporting a significant number of new FDA-approved drugs. Additional details about the earnings will be available on their Investor Relations website.
Read more →-LH
May 28, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Christin O'Donnell - 336-436-5076 Investor Labcorp.com Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com Labcorp to Speak at the 44th Annual William Blair Gr
Labcorp (NYSE LH) announced that its executive management team will present at the 44th Annual William Blair Growth Stock Conference on June 4, 2024. The company is recognized as a leader in innovative laboratory services, supporting healthcare professionals and patients globally. Labcorp's contributions include providing insights that have supported a significant percentage of new FDA drug approvals and conducting millions of tests worldwide. This event highlights Labcorp's ongoing commitment to advancing health and science.
Read more →-LH
Apr 25, 2024Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2024 First Quarter Results Updates Full
Labcorp has reported strong first-quarter results for 2024, with revenue rising 4.6% to $3.18 billion and diluted EPS increasing to $2.69. The company announced an adjustment in its full-year EPS guidance upwards, reflecting a robust operational performance bolstered by strategic acquisitions. Notably, Labcorp has expanded its testing capabilities in key therapeutic areas and has landed numerous partnerships. However, challenges remain, including a decrease in operating cash flow and persistent high debt levels.
Read more →-LH
Mar 27, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com Investors Christin O'Donnell - 336-436-5076 Investor Labcorp.com Labcorp to Announce First Quarter Financial Results
Labcorp (NYSE: LH) is set to announce its financial results for the first quarter of 2024 on April 25, 2024, before market opening. A conference call and webcast will follow at 9 a.m. ET to discuss the results. The company emphasizes its role in supporting the pharmaceutical industry, having contributed to a significant percentage of FDA approvals in 2023. The earnings press release will be available on the Labcorp Investor Relations website.
Read more →-LH
Feb 15, 2024Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2023 Fourth Quarter and Full Year Resul
Labcorp (NYSE LH) has reported fourth quarter and full year results for 2023, highlighting revenue growth despite significant financial challenges. The company experienced a net loss of $166.8 million for Q4, contrasting with net earnings in the previous year. While Labcorp's adjusted EPS for the fourth quarter saw a modest rise, overall financial metrics like operating income and free cash flow showed declines compared to prior periods. Looking ahead, Labcorp has provided guidance for 2024 that suggests anticipated adjustments in earnings and cash flow.
Read more →-LH
Jan 16, 2024Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Christin O'Donnell - 336-436-5076 Investor Labcorp.com Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 202
Labcorp (NYSE: LH) is scheduled to announce its financial results for the fourth quarter and full year of 2023 on February 15, 2024, ahead of the market opening. A conference call and webcast for further discussion of the results will take place at 9 a.m. ET on the same day. Interested parties can access the earnings press release on the Labcorp Investor Relations website. The company is recognized for its innovative laboratory services and significant contributions to the drug development industry.
Read more →-LH
Jan 2, 2024Document FOR IMMEDIATE RELEASE LabCorp Contacts Media Kimbrel Arculeo - 336-436-8263 Media Labcorp.com Investors Relations Christin O'Donnell - 336-436-5076 Investor Labcorp.com LABCORP TO SPEAK AT THE 42ND
Labcorp (NYSE LH) announced its participation in the upcoming 42nd Annual J.P. Morgan Healthcare Conference, where members of its executive management will engage in a fireside chat. The event is scheduled for January 9 at 4:30 p.m. PT. A live audio webcast will be available on the company's Investor Relations website, allowing stakeholders and the public to follow the discussion. Labcorp is recognized for its extensive laboratory services, supporting medical professionals and researchers worldwide.
Read more →-LH
Oct 26, 2023Document FOR IMMEDIATE RELEASE Contact Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2023 Third Quarter Results Company Upda
Labcorp reported its third quarter results for 2023, showing a revenue increase of 6.6% year-over-year. Despite a strong performance in diagnostic services, net earnings and dilute EPS significantly decreased compared to the previous year. The company also launched a new Alzheimer's diagnostic test and updated their full-year guidance. However, a decrease in COVID-19 related testing has negatively impacted overall profitability.
Read more →-LH
Sep 29, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESU
Labcorp is set to release its financial results for the third quarter of 2023 on October 26, 2023. A conference call and webcast will follow the announcement at 9 a.m. ET to discuss the outcomes. Labcorp, which employs over 60,000 individuals and operates globally, plays a crucial role in laboratory services for various stakeholders, having contributed significantly to FDA-approved drugs and millions of tests worldwide.
Read more →-LH
Sep 14, 2023Document Labcorp Contacts Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp to Present Strategy, Business and Financial Outlook at Investo
Labcorp (NYSE LH) is hosting an Investor Day where they will present their strategic vision, business overview, and financial outlook to stakeholders. CEO Adam Schechter highlighted the company's commitment to innovation and operational excellence to drive profitable growth. The event will feature discussions on Labcorp's capabilities in diagnostics and biopharma services. A live webcast of the event will be available, alongside a replay on the company's Investor Relations site.
Read more →-LH
Jul 31, 2023Document FOR IMMEDIATE RELEASE LabCorp Contacts Christin O'Donnell (investors) - 336-436-5076 Investor Labcorp.com Kimbrel Arculeo (media) - 336-436-8263 Media Labcorp.com Labcorp to Host Investor Day on
Labcorp announced an upcoming Investor Day scheduled for September 14, 2023, in New York City. The event will feature presentations from CEO Adam Schechter outlining the company's future strategy and financial outlook. Additionally, there will be a Q&A session for investor inquiries. The event aims to enhance transparency and engagement with stakeholders through a live webcast.
Read more →-LH
Jul 27, 2023Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Rachael Valdez (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2023 Second Quarter Results Company Provides Full
Labcorp (NYSE: LH) reported its second quarter results for 2023, showing a revenue increase of 4% to $3.03 billion. The company provided full-year guidance with an adjusted EPS forecast of $13.00 to $14.00. The recent spin-off of Fortrea resulted in a $1.6 billion cash distribution, part of which will fund a share repurchase program. Despite positive growth in the Base Business, diluted EPS and free cash flow experienced significant declines compared to the previous year due to reduced COVID-19 testing revenues and higher expenses.
Read more →-LH
Jul 13, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com
Labcorp (NYSE: LH) has announced the declaration of a quarterly cash dividend of $0.72 per share of common stock. This dividend is scheduled to be payable on September 8, 2023, to stockholders who are on record as of August 8, 2023. The announcement signifies Labcorp's commitment to providing returns to its shareholders.
Read more →-LH
Jul 3, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com LABCORP COMPLETES SPIN-OFF
Labcorp has successfully completed the spin-off of Fortrea, an independent Contract Research Organization. The spin-off, designed to enhance customer service and shareholder value, resulted in a cash distribution of approximately $1.6 billion to Labcorp. Stockholders received shares of Fortrea for every Labcorp share held, with no action required on their part. The consolidation aims to improve operational efficiency while adhering to tax-free structuring for stakeholders. Despite this, uncertainty exists regarding the future impact of the separation and associated transition challenges.
Read more →-LH
Jun 29, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 2
Labcorp (NYSE: LH) will announce its second quarter financial results on July 27, 2023, prior to market opening. A conference call and webcast will follow at 9 a.m. ET to discuss the results. Investors can access the earnings press release on the Labcorp Investor Relations website, where they can also find information on registering for the call. The webcast will be available for replay for one year after the event.
Read more →-LH
Jun 12, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com Labcorp Announces Additional Information in Connection with it
Labcorp has announced additional details regarding the spin-off of Fortrea Holdings Inc., including record and distribution dates. The record date is set for June 20, 2023, with distribution on June 30, 2023. Shareholders will receive one share of Fortrea for each Labcorp share held. The SEC has declared the Registration Statement for Fortrea effective, with trading expected to begin around June 16, 2023. However, the completion of the spin-off is subject to customary closing conditions, introducing some uncertainties.
Read more →-LH
Jun 9, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com Labcorp Announces Information in Connection with its Spin-off
Labcorp announced the details of its spin-off of Fortrea Holdings Inc., which will take place with a record date on June 20, 2023, and a distribution date on June 30, 2023. Shareholders of Labcorp will receive one share of Fortrea for each share held as of the record date. This spin-off is anticipated to enhance Labcorp's focus on clinical development and commercialization services. However, the successful completion of the spin-off is contingent upon customary closing conditions and other risks.
Read more →-LH
Jun 8, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Rachael Valdez - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com Labcorp Announces Launch of Fortrea's Notes Offering in Connec
Labcorp has announced the launch of senior secured notes by its subsidiary Fortrea, in anticipation of a spinoff into a separate publicly traded company. This offering aims to generate approximately $1,605 million to fund part of the assets contributed to Fortrea and related expenses. The notes will be secured and subject to customary closing conditions, with proceeds held in escrow until specific conditions are fulfilled. However, several risks could impact the successful completion of both the offering and the spinoff.
Read more →-LH
Apr 25, 2023Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Brandi Martin (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2023 First Quarter Results Company Updates Full-Ye
Labcorp has reported its first quarter results for 2023, revealing a 10% growth in Base Business revenue, although total revenue declined to $3.78 billion, down 3.1% from $3.90 billion last year. The significant drop in COVID-19 Testing has impacted earnings, with diluted EPS falling to $2.39 compared to $5.23 in the previous year. The company plans to proceed with the spin-off of its Clinical Development business, now branded as Fortrea, expected by mid-year 2023. Despite a challenging quarter, Labcorp remains optimistic about its strategic plan and future growth potential.
Read more →-LH
Apr 6, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Brandi Martin - 336-436-8263 Media Labcorp.com
Labcorp has announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. This dividend is set to be paid on June 8, 2023, to stockholders who are on record as of May 18, 2023. The announcement highlights Labcorp's solid financial standing and commitment to providing returns to its investors.
Read more →-LH
Mar 31, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Brandi Martin - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 25
Labcorp (NYSE LH) has announced that it will release its first quarter financial results for the year 2023 before the market opens on April 25, 2023. A conference call and webcast will follow, providing insights into the company's performance. Investors can access the live and recorded versions of this session on the Labcorp Investor Relations website.
Read more →-LH
Feb 16, 2023Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Brandi Martin (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2022 Fourth Quarter and Full-Year Results Company
Labcorp reported its fourth quarter and full-year results for 2022, indicating a decline in revenue and earnings compared to the previous year. Revenue for Q4 was $3.7 billion, a drop from $4.1 billion in the previous year, while the full-year revenue also saw a decrease from $16.1 billion to $14.9 billion. The diluted EPS for Q4 decreased significantly to $0.86 from $5.75, and the year-end EPS was down to $13.97 from $24.39. Despite these declines, Labcorp has plans for future growth, including share repurchase opportunities and the launch of new products.
Read more →-LH
Jan 18, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Brandi Martin - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FOURTH QUARTER FINANCIAL RESULTS ON FEBRUAR
Labcorp (NYSE: LH) will announce its fourth quarter financial results for 2022 on February 16, 2023. The announcement will be made before the market opens, followed by a conference call and webcast at 9 a.m. ET that same day. Investors and media are invited to participate, and a replay of the webcast will be available shortly after the live event.
Read more →-LH
Jan 5, 2023Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Brandi Martin - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com THOMAS PIKE TO JOIN LABCORP AS PRESIDENT AND CHIEF EXECUTIVE OF
Labcorp has announced the appointment of Thomas Pike as the new president and CEO of its Drug Development Clinical Development business unit, effective January 9, 2023. With over 30 years of industry experience, Pike aims to drive growth and innovation, especially in light of the planned spin-off of the Clinical Development business, expected in mid-2023. His successful leadership at Quintiles and other organizations highlights his suitability for this role. The transition period will also see Paul Kirchgraber leaving the CEO role of Labcorp's Drug Development to focus on other initiatives.
Read more →-LH
Jan 3, 2023Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT THE 41ST
LabCorp has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference taking place on January 10, 2023. Members of LabCorp's executive management team will be involved in a fireside chat during the event. A live webcast of the discussion will be available on the Company's Investor Relations website, allowing stakeholders to engage with LabCorp's insights and updates. The archived version will also be accessible for later viewing.
Read more →-LH
Oct 31, 2022Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT THE CREDIT SUISSE 31ST
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 LABCORP TO SPEAK AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Oct. 31, 2022 - Labcorp (NYSE LH), a leading global life sciences company, today announced th
Read more →-LH
Oct 27, 2022▼ -5.9%on this newsshared move
Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Rachael Valdez (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2022 Third Quarter Results Company Updates Full-Y
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Rachael Valdez (media) - 336-436-8263 Labcorp Announces 2022 Third Quarter Results Company Updates Full-Year Guidance Revenue Q3 of $3.6 billion versus $4.1 billion last year Diluted EPS Q3 of $3.90 versus $6
Read more →-LH
Oct 13, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Rachael Valdez - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com
Media Rachael Valdez - 336-436-8263 Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP APPOINTS GOOGLE CLOUD EXECUTIVE KIRSTEN KLIPHOUSE TO ITS BOARD OF DIRECTORS BURLINGTON, N.C., Oct. 13, 2022 - Labcorp (NYSE LH), a leading global life sciences company, today a
Read more →-LH
Sep 27, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Rachael Valdez - 336-436-8263 LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER 27, 2022 BURLINGTON, N.C., Sept. 27, 2022 - Labcorp (NYSE LH), a leading global life sciences company, will release its f
Read more →-LH
Sep 6, 2022Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT THE BAIRD 2022
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO SPEAK AT THE BAIRD 2022 GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Sept. 6, 2022 - Labcorp (NYSE LH), a leading global life sciences company, today announce
Read more →-LH
Jul 28, 2022Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com Labcorp to Spin Off Clinical Development Business Clinical Development Business to be
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Labcorp to Spin Off Clinical Development Business Clinical Development Business to be a Leading, Pure-Play Contract Research Organization with a Comprehensive
Read more →-LH
Jul 14, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESU
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 28, 2022 BURLINGTON, N.C., July 14, 2022 - Labcorp (NYSE LH), a leading global life sciences company, will rel
Read more →-LH
May 17, 2022Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT THE UBS 2022
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO SPEAK AT THE UBS 2022 GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., May 17, 2022 - Labcorp (NYSE LH), a leading global life sciences company, today announced t
Read more →-LH
Apr 28, 2022Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2022 First Quarter Results Company R
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Labcorp Announces 2022 First Quarter Results Company Raises Full-Year Revenue and EPS Guidance Revenue Q1 of $3.9 billion versus $4.2 billion last year Dilut
Read more →-LH
Apr 7, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Michele Mazur - 336-436-8263 Media Labcorp.com
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Michele Mazur - 336-436-8263 LABCORP INITIATES QUARTERLY DIVIDEND BURLINGTON, N.C., April 7, 2022 - Labcorp (NYSE LH) (the Company), a leading global life sciences company, announced today that its Board of Directo
Read more →-LH
Mar 28, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESUL
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 28, 2022 BURLINGTON, N.C., March 28, 2022 - Labcorp (NYSE LH), a leading global life sciences company, will re
Read more →-LH
Feb 10, 2022Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Michele Mazur (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2021 Fourth Quarter and Full-Year Results Company
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Michele Mazur (media) - 336-436-8263 Labcorp Announces 2021 Fourth Quarter and Full-Year Results Company Provides 2022 Guidance and Longer-Term Outlook (2022-2024) Revenue Q4 of $4.1 billion, versus $4.5 billi
Read more →-LH
Feb 9, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Michele Mazur - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP ENTERS COMPREHENSIVE, LONG-TERM LABORATORY RELATIONSHIP
Media Michele Mazur - 336-436-8263 Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP ENTERS COMPREHENSIVE, LONG-TERM LABORATORY RELATIONSHIP WITH ASCENSION Arrangement Includes Labcorp's Acquisition of Certain Outreach Laboratory Assets Strategic Collaboration
Read more →-LH
Jan 10, 2022Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Michele Mazur - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Michele Mazur - 336-436-8263 LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS ON FEBRUARY 10, 2022 BURLINGTON, N.C., Jan. 10, 2022 - Labcorp (NYSE LH), a leading global life sciences company,
Read more →-LH
Jan 4, 2022Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP IS SCHEDULED TO VIRTUALLY PARTICIPATE AT
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP IS SCHEDULED TO VIRTUALLY PARTICIPATE AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE BURLINGTON, N.C., Jan. 4, 2022 - Labcorp (NYSE LH), a leading global li
Read more →-LH
Dec 9, 2021▼ -5%on this news
Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP ANNOUNCES INITIATIVES TO ENHANCE SHAREHOLDER VA
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP ANNOUNCES INITIATIVES TO ENHANCE SHAREHOLDER VALUE Board of Directors Approves Plans to Initiate Quarterly Cash Dividend and Authorizes $2.5 Billion Share Repurchase Pr
Read more →-LH
Nov 2, 2021Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT CREDIT SUISSE 30TH
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO SPEAK AT CREDIT SUISSE 30TH ANNUAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Nov. 2, 2021 - Labcorp (NYSE LH), a leading global life sciences company, today annou
Read more →-LH
Oct 28, 2021Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2021 Third Quarter Results Company R
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Labcorp Announces 2021 Third Quarter Results Company Raises Full-Year Guidance Revenue Q3 of $4.1 billion, versus $3.9 billion last year Diluted EPS Q3 of $6
Read more →-LH
Sep 28, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER 28, 2021 BURLINGTON, N.C., Sept. 28, 2021 - Labcorp (NYSE LH), a leading global life sciences company, will releas
Read more →-LH
Sep 13, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP COMPLETES ACQUISITION OF MYRIAD AUTOIMMUNE'S
Media Chris Allman-Bradshaw - 336-436-8263 Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP COMPLETES ACQUISITION OF MYRIAD AUTOIMMUNE'S VECTRA TESTING BUSINESS BURLINGTON, N.C., Sept. 13, 2021 - Labcorp (NYSE LH), a leading global life sciences company, today
Read more →-LH
Sep 8, 2021Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO SPEAK AT MORGAN STANLEY 19TH
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP TO SPEAK AT MORGAN STANLEY 19TH ANNUAL GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Sept. 8, 2021 - Labcorp (NYSE LH), a leading global life sciences company, to
Read more →-LH
Aug 12, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP EXTENDS LEADERSHIP IN WOMEN'S HEALTH WITH ACQUI
Media Chris Allman-Bradshaw - 336-436-8263 Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP EXTENDS LEADERSHIP IN WOMEN'S HEALTH WITH ACQUISITION OF OVIA HEALTH Transaction Improves Patient Experience, Patient Outcomes and Aims to Reduce Health Care Costs BURL
Read more →-LH
Jul 29, 2021Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2021 Second Quarter Results Company
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Labcorp Announces 2021 Second Quarter Results Company Raises Full Year Guidance Revenue Q2 of $3.8 billion, versus $2.8 billion last year Diluted EPS Q2 of $
Read more →-LH
Jul 2, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 29, 2021 BURLINGTON, N.C., July 2, 2021 - Labcorp (NYSE LH), a leading global life sciences company, will release it
Read more →-LH
May 18, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP TO SPEAK AT UBS GLOBAL HEALTHCARE VIRTUAL CONFERENCE BURLINGTON, N.C., May 18, 2021 - Labcorp (NYSE LH), a leading global life sciences company, today announced that mem
Read more →-LH
May 14, 2021Labcorp Contacts: Media: Christopher Allman-Bradshaw 336-436-8263 Media@Labcorp.com Investors: Chas Cook 336-436-5076 Investor@Labcorp.com LABCORP PRICES $500,000,000 IN 1.550% SENIOR NOTES DUE 2026
Media: Christopher Allman-Bradshaw 336-436-8263 Investors: Chas Cook 336-436-5076 Investor@Labcorp.com $500,000,000 IN 1.550% SENIOR NOTES DUE 2026 AND $500,000,000 IN 2.700% SENIOR NOTES DUE 2031 May 12, 2021 Labcorp (NYSE: LH) ( Labcorp ) announced today that it has priced
Read more →-LH
May 12, 2021Labcorp Contacts: Media: Christopher Allman-Bradshaw 336-436-8263 Media@Labcorp.com Investors: Chas Cook 336-436-5076 Investor@Labcorp.com
Media: Christopher Allman-Bradshaw Investors: Chas Cook 336-436-5076 Investor@Labcorp.com PROPOSED SALE OF SENIOR NOTES BURLINGTON, N.C., May 12, 2021 Labcorp (NYSE: LH) ( Labcorp ) announced today that it plans to offer, subject to market and other conditions, senior notes
Read more →-LH
Apr 29, 2021Document FOR IMMEDIATE RELEASE Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com Labcorp Announces 2021 First Quarter Results Company R
Contact Chas Cook (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Labcorp Announces 2021 First Quarter Results Company Raises Full Year Guidance Revenue Q1 of $4.2 billion, up from $2.8 billion last year Diluted EPS Q1 of $
Read more →-LH
Mar 30, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 29, 2021 BURLINGTON, N.C., March 30, 2021-- Labcorp (NYSE LH), a leading global life sciences company, will release
Read more →-LH
Mar 26, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP APPOINTS JOHNSON JOHNSON EXECUTIVE KATHRYN WENG
Media Chris Allman-Bradshaw - 336-436-8263 Investors Chas Cook - 336-436-5076 Investor Labcorp.com LABCORP APPOINTS JOHNSON JOHNSON EXECUTIVE KATHRYN WENGEL TO THE BOARD OF DIRECTORS Healthcare Veteran Brings Significant Global Industry Experience BURLINGTON, N.C., March 26
Read more →-LH
Mar 19, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP SCHEDULED TO SPEAK AT KEYBANC CAPITAL MARKETS'
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP SCHEDULED TO SPEAK AT KEYBANC CAPITAL MARKETS' LIFE SCIENCES AND MEDTECH INVESTOR FORUM BURLINGTON, N.C. - March 19, 2021 - Labcorp (NYSE LH), a leading global life scie
Read more →-LH
Feb 23, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP IS SCHEDULED TO SPEAK AT CITI'S 2021 HEALTHCARE
Investors Chas Cook - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP IS SCHEDULED TO SPEAK AT CITI'S 2021 HEALTHCARE SERVICES, MEDTECH, TOOLS, HCIT VIRTUAL CONFERENCE BURLINGTON, N.C., Feb. 23, 2021 - Labcorp (NYSE LH), a leading global l
Read more →-LH
Feb 11, 2021Document FOR IMMEDIATE RELEASE Contact Clarissa Willett (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 Media Labcorp.com LABCORP ANNOUNCES 2020 FOURTH QUARTER AND FULL
Contact Clarissa Willett (investors) - 336-436-5076 Investor Labcorp.com Christopher Allman-Bradshaw (media) - 336-436-8263 2020 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2021 GUIDANCE Revenue Q4 of $4.5 billion, up from $3.0 billion last year Full year of $14.0 bill
Read more →-LH
Jan 8, 2021Document FOR IMMEDIATE RELEASE Labcorp Contacts Investors Clarissa Willett - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR
Investors Clarissa Willett - 336-436-5076 Investor Labcorp.com Media Chris Allman-Bradshaw - 336-436-8263 LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS ON FEBRUARY 11, 2021 BURLINGTON, N.C., January 8, 2021 - Labcorp (NYSE LH), a leading global life
Read more →-LH
Jan 5, 2021Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Clarissa Willett - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media Labcorp.com LABCORP IS SCHEDULED TO VIRTUALLY PARTICIP
Investors Clarissa Willett - 336-436-5076 Investor Labcorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP IS SCHEDULED TO VIRTUALLY PARTICIPATE AT THE 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE BURLINGTON, N.C., Jan. 5, 2021 - Labcorp (NYSE LH), a leading gl
Read more →-LH
Nov 25, 2020Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Christopher Allman-Bradshaw - 336-436-8263 Media LabCorp.com LABCORP IS SCHEDULED TO PRESENT AT THE 202
Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Christopher Allman-Bradshaw - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE 2020 EVERCORE ISI 3RD ANNUAL HEALTHCONX CONFERENCE BURLINGTON, N.C., Nov. 25, 2020 - LabCorp (NYSE LH) today announced that
Read more →-LH
Nov 2, 2020Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Don Von Hagen - 336-436-8263 Media LabCorp.com LABCORP IS SCHEDULED TO PRESENT AT THE 29TH
Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Don Von Hagen - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE 29TH ANNUAL CREDIT SUISSE VIRTUAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Nov. 2, 2020 - LabCorp (NYSE LH) today announced that members of
Read more →-LH
Oct 27, 2020Document FOR IMMEDIATE RELEASE Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Don Von Hagen (media) - 336-436-8263 Media LabCorp.com LABCORP ANNOUNCES 2020 THIRD QUARTER RESULTS Q3 revenue of $3
Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Don Von Hagen (media) - 336-436-8263 LABCORP ANNOUNCES 2020 THIRD QUARTER RESULTS Q3 revenue of $3.9 billion, up from $2.9 billion last year Q3 diluted EPS of $7.17, up from $2.25 last year Q3 adjusted
Read more →-LH
Sep 28, 2020Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Media Donald Von Hagen - 336-436-8263 Media LabCorp.com LABCORP TO ANNOUNCE THIRD QUARTER FINANCI
Investors Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Media Donald Von Hagen - 336-436-8263 LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER 27, 2020 BURLINGTON, N.C., September 28, 2020 - LabCorp (NYSE LH) will release its third quarter of
Read more →-LH
Sep 10, 2020Document Labcorp Contacts Media Donald Von Hagen - 336-436-8263 Media LabCorp.com Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com LABCORP ACQUIRES CLINICAL AMBULATORY LABORATORY BUSINESS OF FRANCISCAN MISS
Media Donald Von Hagen - 336-436-8263 Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com LABCORP ACQUIRES CLINICAL AMBULATORY LABORATORY BUSINESS OF FRANCISCAN MISSIONARIES OF OUR LADY HEALTH SYSTEM LabCorp Expands Services in Louisiana and Mississippi Through Acq
Read more →-LH
Sep 1, 2020Document FOR IMMEDIATE RELEASE LabCorp Contacts Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Pattie Kushner - 336-436-8263 Media LabCorp.com LABCORP IS SCHEDULED TO PRESENT AT THE BAIRD'S 2020
Investors Clarissa Willett - 336-436-5076 Investor LabCorp.com Media Pattie Kushner - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE BAIRD'S 2020 GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., Sept. 1, 2020 - LabCorp (NYSE LH) today announced that members of the executi
Read more →-LH
Jul 28, 2020Document FOR IMMEDIATE RELEASE Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Pattie Kushner (media) - 336-436-8263 Media LabCorp.com LABCORP ANNOUNCES 2020 SECOND QUARTER RESULTS Q2 revenue of
Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Pattie Kushner (media) - 336-436-8263 LABCORP ANNOUNCES 2020 SECOND QUARTER RESULTS Q2 revenue of $2.8 billion, down (4%) from $2.9 billion last year Q2 diluted EPS of $2.37, up 23% from $1.93 last year
Read more →-LH
Jul 6, 2020Document FOR IMMEDIATE RELEASE Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Pattie Kushner (media) - 336-436-8263 Media LabCorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY
Contact Clarissa Willett (investors) - 336-436-5076 Investor LabCorp.com Pattie Kushner (media) - 336-436-8263 LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 28, 2020 BURLINGTON, N.C., July 6, 2020 - LabCorp (NYSE LH) will release its second quarter of 2020 fin
Read more →-LH
May 6, 2020This press release contains forward-looking statements, including but not limited to statements with respect to the impact of various factors on operating and financial results and
Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE BANK OF AMERICA SECURITIES 2020 HEALTH CARE CONFERENCE BURLINGTON, N.C., May 6, 2020 - LabCorp (NYSE: LH) today announced that members
Read more →-LH
May 5, 2020This press release contains forward-looking statements, including but not limited to statements with respect to the Company's corporate governance, leadership, future operations an
Clarissa Willett (investors) - 336-436-5076 Investor@LabCorp.com Pattie Kushner (media) - 336-436-8263 LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS BURLINGTON, N.C., May 5, 2020 - LabCorp (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webc
Read more →-LH
Apr 29, 2020The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.
Contact: Clarissa Willett (investors) - 336-436-5076 Investor@LabCorp.com Pattie Kushner (media) - 336-436-8263 LABCORP ANNOUNCES 2020 FIRST QUARTER RESULTS BURLINGTON, N.C., April 29, 2020 - LabCorp (or the Company) (NYSE: LH) today announced results for the first quarter en
Read more →-LH
Apr 6, 2020This press release contains forward-looking statements, including, but not limited to, statements with respect to the impact of various factors on operating and financial results,
Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS BURLINGTON, N.C., April 6, 2020 - LabCorp (NYSE: LH) will release its first quarter of 2020 financial res
Read more →-LH
Mar 2, 2020LabCorp Contacts: Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com LABCORP IS SCHEDULED TO PRESENT AT THE 2020
Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE 2020 BARCLAYS GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., March 2, 2020 -LabCorp (NYSE: LH) today announced that members of the exec
Read more →-LH
Jan 6, 2020LabCorp Contacts: Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com LABCORP IS SCHEDULED TO PRESENT AT THE 38TH
Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner - 336-436-8263 LABCORP IS SCHEDULED TO PRESENT AT THE 38TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE BURLINGTON, N.C., Jan. 6, 2020 - LabCorp (NYSE: LH) today announced that members of the e
Read more →-LH
Dec 3, 2019LabCorp Contacts: Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner 336-436-8263 Media@LabCorp.com LABCORP ANNOUNCES EARLY RESULTS OF ITS TENDER OFFER FOR UP TO $30
Investors: Clarissa Willett Investor@LabCorp.com Media: Pattie Kushner 336-436-8263 EARLY RESULTS OF ITS TENDER OFFER FOR UP TO $300,000,000 PRINCIPAL AMOUNT OF ITS OUTSTANDING 4.625% SENIOR NOTES DUE 2020 BURLINGTON, N.C., Dec. 3, 2019 LabCorp (NYSE: LH) announced today the
Read more →-LH
Nov 26, 2019LabCorp Contacts: Media: Pattie Kushner 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com LABCORP APPOINTS SENIOR FINANCE EXECUTIVE JEFFREY A. DAVIS TO ITS
Media: Pattie Kushner 336-436-8263 Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com SENIOR FINANCE EXECUTIVE JEFFREY A. DAVIS TO ITS BOARD OF DIRECTORS Current CFO of Qurate Retail Group and Former CFO of J. C. Penney Brings More Than 30 Years of Finance Experi
Read more →-LH
Nov 19, 2019LabCorp Contacts: Media: Pattie Kushner 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com CONVERSION RIGHT TRIGGERED FOR LABCORP S ZERO COUPON CONVERTIBLE
Media: Pattie Kushner 336-436-8263 Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com TRIGGERED FOR LABCORP S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 BURLINGTON, N.C., Nov. 19, 2019 LabCorp (NYSE: LH) announced today that it has provided notice of its
Read more →-LH
Nov 18, 2019LabCorp Contacts: Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner 336-436-8263 Media@LabCorp.com LABCORP PRICES $ 400,000,000 IN 2.300% SENIOR NOTES DUE 20 24 AND
Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com Media: Pattie Kushner 336-436-8263 $400,000,000 IN 2.300% SENIOR NOTES DUE 2024 AND $650,000,000 IN 2.950% SENIOR NOTES DUE BURLINGTON, N.C., Nov. 18, 2019 LabCorp (NYSE: LH) announced today that it has priced it
Read more →-LH
Nov 6, 2019LabCorp Contacts: Media: Pattie Kushner 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com LABCORP ANNOUNCES DEPARTURE OF JOHN RATLIFF, NAMES NEW LABCORP DI
Media: Pattie Kushner 336-436-8263 Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com DEPARTURE OF JOHN RATLIFF, NAMES NEW LABCORP DIAGNOSTICS LEADERSHIP BURLINGTON, N.C., Nov. 6, 2019 LabCorp (NYSE: LH), a leading global life sciences company, today announced th
Read more →-LH
Oct 22, 2019LabCorp Contacts: Media: Donald Von Hagen - 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com LABCORP EXPANDS SERVICES IN NORTHWEST INDIANA AND SURROUNDI
Media: Donald Von Hagen - 336-436-8263 Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com LABCORP EXPANDS SERVICES IN NORTHWEST INDIANA AND SURROUNDING REGION THROUGH ACQUISITION OF DIAGNOSTIC CLINICAL LABORATORY ASSETS FROM SOUTH BEND MEDICAL FOUNDATION South Be
Read more →-LH
Oct 15, 2019LabCorp Contacts: Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com CONVERSION RIGHT TRIGGERED FOR LABCORP'S ZERO COUPON CONVERTI
Media: Pattie Kushner - 336-436-8263 Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com CONVERSION RIGHT TRIGGERED FOR LABCORP'S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 Burlington, N.C., Oct. 15, 2019 - LabCorp (NYSE: LH) announced today that its Zer
Read more →-LH
Oct 3, 2019LabCorp Contacts: Media: Pattie Kushner 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com LABCORP ANNOUNCES NEW LEADERSHIP ROLES FOR ITS TWO BUSINESS SEGME
Media: Pattie Kushner 336-436-8263 Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com NEW LEADERSHIP ROLES FOR ITS TWO BUSINESS SEGMENTS AND SELECTS NEW CHIEF HUMAN RESOURCES OFFICER BURLINGTON, N.C., Oct. 3, 2019 LabCorp (NYSE: LH), a leading global life sciences
Read more →-LH
Sep 11, 2019LabCorp Contacts: Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com LABCORP'S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021
Media: Pattie Kushner - 336-436-8263 Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com LABCORP'S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 TO ACCRUE CONTINGENT INTEREST BURLINGTON, N.C., September 11, 2019 - LabCorp (NYSE: LH) announced today that for
Read more →-LH
Aug 29, 2019LabCorp Contacts: Media: Pattie Kushner - 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com
Media: Pattie Kushner - 336-436-8263 Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com LABCORP IS SCHEDULED TO PRSENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE BURLINGTON, N.C., August 29, 2019 - LabCorp (NYSE: LH) today announced it will participate a
Read more →-LH
Aug 29, 2019LabCorp Contacts: Media: Sue Maynard --- 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com COVANCE LAUNCHES LABORATORY DATA MANAGEMENT FUNCTIONAL SERVICE
Media: Sue Maynard --- 336-436-8263 Investors: Clarissa Willett - 336-436-5076 Investor@LabCorp.com COVANCE LAUNCHES LABORATORY DATA MANAGEMENT FUNCTIONAL SERVICE PROVIDER FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES Program Expands the Company's Growing and Unique FSPx Ca
Read more →-LH
Jul 25, 2019Clarissa Willett (investors) - 336-436-5076 Investor@labcorp.com Pattie Kushner (media) - 336-436-8263 Media@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlingto
Contact: Clarissa Willett (investors) - 336-436-5076 Investor@labcorp.com Pattie Kushner (media) - 336-436-8263 Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 LABCORP ANNOUNCES 2019 SECOND QUARTER RESULTS AND UPDA
Read more →-LH
Jul 22, 2019LabCorp Contacts: Don Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com LABCORP EXPANDS CONSUMER-INITIATED TEST OFFERING Pixel by
LabCorp Contacts: Don Von Hagen (media) Clarissa Willett (investors) Investor@labcorp.com LABCORP EXPANDS CONSUMER-INITIATED TEST OFFERING Pixel by LabCorp Now Available with Phlebotomy Collection Through LabCorp's Nationwide Patient Service Center Network BURLINGTON, N.C.,
Read more →-LH
Jul 1, 2019LabCorp Contacts: Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com CONVERSION RIGHT TRIGGERED FOR LABCORP'S ZERO COUPON CONV
LabCorp Contacts: Clarissa Willett (investors) Investor@labcorp.com Pattie Kushner (media) CONVERSION RIGHT TRIGGERED FOR LABCORP'S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 Burlington, N.C., July 1, 2019 - LabCorp (NYSE: LH) announced today that its Zero Coupon Co
Read more →-LH
Jun 25, 2019LabCorp Contacts: Don Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JU
LabCorp Contacts: Don Von Hagen (media) Clarissa Willett (investors) Investor@labcorp.com LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 25, 2019 BURLINGTON, N.C., June 25, 2019 - LabCorp (NYSE: LH) will release its second quarter of 2019 financial results befor
Read more →-LH
Jun 18, 2019LabCorp Contacts: Don Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willet (investors) +1 336-436-5076 Investor@labcorp.com Philips Contact: Silvie Casanova, Philips North America +1
LabCorp Contacts: Don Von Hagen (media) Clarissa Willet (investors) Investor@labcorp.com Philips Contact: Silvie Casanova, Philips North America silvie.casanova@philips.com LABCORP AND MOUNT SINAI HEALTH SYSTEM COLLAORATE TO ESTABLISH DIGITAL AND AI-ENABLED PATHOLOGY CENTER
Read more →-LH
Jun 7, 2019LabCorp Contacts: Don Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com LABCORP AND QIAGEN ANNOUNCE NEW THERASCREEN PIK3CA MUTATIO
LabCorp Contacts: Don Von Hagen (media) Clarissa Willett (investors) Investor@labcorp.com LABCORP AND QIAGEN ANNOUNCE NEW THERASCREEN PIK3CA MUTATION ANALYSIS COMPANION DIAGNOSTIC FOR METASTATIC BREAST CANCER New Therapy Specifically for Patients with PIK3CA Mutation in HR+/
Read more →-LH
Jun 5, 2019LabCorp Contacts: Media: Pattie Kushner 336-436-8263 Media@LabCorp.com Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com LABCORP ANNOUNCES NEW LEADERSHIP ROLES David P. King, current cha
Media: Pattie Kushner 336-436-8263 Investors: Clarissa Willett 336-436-5076 Investor@LabCorp.com NEW LEADERSHIP ROLES BURLINGTON, N.C., June 5, 2019 LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced t
Read more →-LH
Jun 3, 2019LabCorp Contacts: Media : Sue Maynard: +1 336-436-8263 Media@labcorp.com Envigo Contact: Oscar Perez: +1 317-806-6080 Marketing@Envigo.com Investors: Clarissa Willett: +1 336-436-5076 Investor@labco
LabCorp Contacts: Media : Sue Maynard: +1 336-436-8263 Media@labcorp.com Envigo Contact: Oscar Perez: +1 317-806-6080 Marketing@Envigo.com Investors: Clarissa Willett: +1 336-436-5076 Investor@labcorp.com LABCORP AND ENVIGO COMPLETE INNOVATIVE TRANSACTIONS LabCorp Acquires E
Read more →-LH
May 10, 2019LabCorp Contacts: Donald Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willet (investors) +1 336-436-5076 Investor@labcorp.com LABCORP ANNOUNCES AVAILABILITY OF NEW QIAGEN THERASCREEN
LabCorp Contacts: Donald Von Hagen (media) Clarissa Willet (investors) Investor@labcorp.com LABCORP ANNOUNCES AVAILABILITY OF NEW QIAGEN THERASCREEN FGFR MUTATION ANALYSIS COMPANION DIAGNOSTIC FOR BLADDER CANCER New Test Further Underscores LabCorp's Leadership in Development
Read more →-LH
May 2, 2019LabCorp Contacts: Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS Bur
LabCorp Contacts: Clarissa Willett (investors) Investor@labcorp.com Pattie Kushner (media) LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS Burlington, N.C., May 2, 2019 - LabCorp (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beg
Read more →-LH
Apr 17, 2019LabCorp Contacts: Envigo Contact: Media : Sue Maynard: +1 336-436-8263 Paul Surdez: +1 732-873-6682 Media@labcorp.com paul.surdez@envigo.com Investors: Clarissa Willett: +1 336-436-5076 Investor@lab
LabCorp Contacts: Envigo Contact: Media : Sue Maynard: +1 336-436-8263 Paul Surdez: +1 732-873-6682 Media@labcorp.com paul.surdez@envigo.com Investors: Clarissa Willett: +1 336-436-5076 Investor@labcorp.com LABCORP AND ENVIGO SIGN INNOVATIVE AGREEMENT TO EXPAND COVANCE S
Read more →-LH
Apr 1, 2019LabCorp Contacts: Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com LabCorp to Announce FIRST Quarter Financial Results on
LabCorp Contacts: Clarissa Willett (investors) Investor@labcorp.com Pattie Kushner (media) LabCorp to Announce FIRST Quarter Financial Results on April 30, 2019 BURLINGTON, N.C., April 1, 2019 - LabCorp (NYSE: LH) will release its first quarter of 2019 financial results befor
Read more →-LH
Mar 28, 2019LabCorp Contacts: Clarissa Willet (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com LABCORP EARNS 100 PERCENT ON HUMAN RIGHTS CAMPAIGN FOUNDAT
LabCorp Contacts: Clarissa Willet (investors) Investor@labcorp.com Pattie Kushner (media) LABCORP EARNS 100 PERCENT ON HUMAN RIGHTS CAMPAIGN FOUNDATION'S 17TH ANNUAL SCORECARD ON LGBTQ WORKPLACE EQUALITY Receives Designation as a Best Place to Work for LGBTQ Equality for Se
Read more →-LH
Mar 11, 2019Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com Clarissa Willett (investors) +1 336-436-5076 Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burling
Contact: Pattie Kushner (media) Clarissa Willett (investors) Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 LABCORP'S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 TO ACCRUE CONTINGENT IN
Read more →-LH
Mar 5, 2019LabCorp Contacts: Clarissa Willet (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com LABCORP IS SCHEDULED TO PRESENT AT THE 2019 BARCLAYS GLOBA
LabCorp Contacts: Clarissa Willet (investors) Investor@labcorp.com Pattie Kushner (media) LABCORP IS SCHEDULED TO PRESENT AT THE 2019 BARCLAYS GLOBAL HEALTHCARE CONFERENCE Burlington, NC, March 5, 2019 -LabCorp (NYSE: LH) today announced it will participate at the 2019 Barcl
Read more →-LH
Feb 19, 2019LabCorp Contacts: Don Von Hagen (media) +1 336-436-8263 Media@labcorp.com Clarissa Willet (investors) +1 336-436-5076 Investor@labcorp.com LABCORP STRENGTHENS LEADERSHIP POSITION IN PRECISION MEDICI
LabCorp Contacts: Don Von Hagen (media) Clarissa Willet (investors) Investor@labcorp.com LABCORP STRENGTHENS LEADERSHIP POSITION IN PRECISION MEDICINE WITH EXPANSION OF THERAPEUTIC DRUG MONITORING PORTFOLIO LabCorp's DoseASSURE Portfolio Provides Most Expansive Biologics TDM
Read more →-LH
Feb 7, 2019Scott Frommer (investors) - 336-436-5076 Investor@labcorp.com Pattie Kushner (media) - 336-436-8263 Media@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington,
Contact: Scott Frommer (investors) - 336-436-5076 Investor@labcorp.com Pattie Kushner (media) - 336-436-8263 Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 2018 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 20
Read more →-LH
Jan 22, 2019Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com Scott Frommer (investors) +1 336-436-5076 Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington
Contact: Pattie Kushner (media) Scott Frommer (investors) Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 LABCORP NAMED TO FORTUNE MAGAZINE'S 2019 LIST OF WORLD'S MOST ADMIRED COMPANIES,' MAKI
Read more →-LH
Jan 16, 2019LabCorp Contacts: Scott Frommer (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com LabCorp to Announce Fourth Quarter and Full Year 2018 Financ
LabCorp Contacts: Scott Frommer (investors) Investor@labcorp.com Pattie Kushner (media) LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019 BURLINGTON, N.C., Jan. 16, 2019 - LabCorp (NYSE: LH) will release its fourth quarter and full ye
Read more →-LH
Jan 3, 2019LabCorp Contacts: Scott Frommer (investors) Genfit Contacts: Naomi Eichenbaum (investors): +1 336-436-5076 +1 617-714-5252 Investor@labcorp.com Investors@genfit.com Sue Maynard (media) H l ne Lavin
LabCorp Contacts: Scott Frommer (investors) Genfit Contacts: Naomi Eichenbaum (investors): +1 336-436-5076 +1 617-714-5252 Investor@labcorp.com Investors@genfit.com Sue Maynard (media) H l ne Lavin (media): +1 336-436-8263 +333 2016-4000 Media@labcorp.com helene.lavin@genfit
Read more →-LH
Jan 2, 2019Scott Frommer (investors) +1 336-436-5076 Investor@labcorp.com Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington
Contact: Scott Frommer (investors) Investor@labcorp.com Pattie Kushner (media) Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 LABCORP IS SCHEDULED TO PRESENT AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE B
Read more →-LH
Dec 7, 2018Sue Maynard (media) +1 336-436-8263 Media@labcorp.com Scott Frommer (investors) +1 336-436-5076 Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington, N
Contact: Sue Maynard (media) Scott Frommer (investors) Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 COVANCE XCELLERATE WINS BEST TECHNOLOGICAL DEVELOPMENT IN CLINICAL TRIALS (CLINICAL SPONSOR
Read more →-LH
Nov 28, 2018LabCorp Contact: Donald Von Hagen (media) Walgreens Contact: Scott Goldberg +1 336-436-8263 +1 847-315-7649 Media@labcorp.com scott.goldberg@walgreens.com Scott Frommer (investors) +1 336-436-5076 I
LabCorp Contact: Donald Von Hagen (media) Walgreens Contact: Scott Goldberg +1 336-436-8263 +1 847-315-7649 Media@labcorp.com scott.goldberg@walgreens.com Scott Frommer (investors) Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington,
Read more →-LH
Nov 8, 2018LabCorp Contact: Pattie Kushner (media) - +1 336-436-8263 Media@labcorp.com Scott Frommer (investors) - +1 336-436-5076 Investor@labcorp.com Horizon Blue Cross Blue Shield of New Jersey Contact: Tho
LabCorp Contact: Pattie Kushner (media) - +1 336-436-8263 Scott Frommer (investors) - +1 336-436-5076 Investor@labcorp.com Horizon Blue Cross Blue Shield of New Jersey Contact: Thomas Vincz (media) - +1 973-466-6625 Thomas_Vincz@HorizonBlue.com LabCorp and Horizon Blue Cross
Read more →-LH
Nov 1, 2018Donald Von Hagen (media) +1 336-436-8263 Media@labcorp.com Scott Frommer (investors) +1 336-436-5076 Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlingt
Contact: Donald Von Hagen (media) Scott Frommer (investors) Investor@labcorp.com Company Information: www.labcorp.com 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 LABCORP LAUNCHES CONSUMER-INITIATED WELLNESS TEST OFFERING Pixel by LabCorp Offers Se
Read more →Competitive Position
How LH ranks across every disease it competes inCompetitive Position is a premium feature
See how LH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial